# A Study on the Efficacy of Disitamab Vedotin in Advanced HER2-positive Paget's Disease.

> **NCT06561555** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 36 (estimated)

## Conditions studied

- Mammary or Extramammary Paget's Disease

## Interventions

- **DRUG:** RC48

## Key facts

- **NCT ID:** NCT06561555
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-15
- **Primary completion:** 2025-08-15
- **Final completion:** 2027-08-15
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2024-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06561555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06561555, "A Study on the Efficacy of Disitamab Vedotin in Advanced HER2-positive Paget's Disease.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06561555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*